TY - JOUR
T1 - Regeneration Through in vivo Cell Fate Reprogramming for Neural Repair
AU - Tai, Wenjiao
AU - Xu, Xiao Ming
AU - Zhang, Chun Li
N1 - Funding Information:
The research in the Zhang laboratory is supported by The Welch Foundation (I-1724), the Decherd Foundation, the Pape Adams Foundation, Kent Waldrep Foundation Center for Basic Research on Nerve Growth and Regeneration, and NIH Grants (NS099073, NS092616, NS088095, and NS093502). Research in the Xu laboratory is supported by NIH 1R01 100531, 1R01 NS103481, and Merit Review Award I01 BX002356, I01 BX003705, I01 RX002687 from the U.S. Department of Veterans Affairs.
PY - 2020/4/24
Y1 - 2020/4/24
N2 - The adult mammalian central nervous system (CNS) has very limited regenerative capacity upon neural injuries or under degenerative conditions. In recent years, however, significant progress has been made on in vivo cell fate reprogramming for neural regeneration. Resident glial cells can be reprogrammed into neuronal progenitors and mature neurons in the CNS of adult mammals. In this review article, we briefly summarize the current knowledge on innate adult neurogenesis under pathological conditions and then focus on induced neurogenesis through cell fate reprogramming. We discuss how the reprogramming process can be regulated and raise critical issues requiring careful considerations to move the field forward. With emerging evidence, we envision that fate reprogramming-based regenerative medicine will have a great potential for treating neurological conditions such as brain injury, spinal cord injury (SCI), Alzheimer’s disease (AD), Parkinson’s disease (PD), and retinopathy.
AB - The adult mammalian central nervous system (CNS) has very limited regenerative capacity upon neural injuries or under degenerative conditions. In recent years, however, significant progress has been made on in vivo cell fate reprogramming for neural regeneration. Resident glial cells can be reprogrammed into neuronal progenitors and mature neurons in the CNS of adult mammals. In this review article, we briefly summarize the current knowledge on innate adult neurogenesis under pathological conditions and then focus on induced neurogenesis through cell fate reprogramming. We discuss how the reprogramming process can be regulated and raise critical issues requiring careful considerations to move the field forward. With emerging evidence, we envision that fate reprogramming-based regenerative medicine will have a great potential for treating neurological conditions such as brain injury, spinal cord injury (SCI), Alzheimer’s disease (AD), Parkinson’s disease (PD), and retinopathy.
KW - Alzheimer’s diseases (AD)
KW - Parkinson’s disease (PD)
KW - adult neurogenesis
KW - in vivo reprogramming
KW - retinopathy
KW - spinal cord injury (SCI)
KW - traumatic brain injury (TBI)
UR - http://www.scopus.com/inward/record.url?scp=85084352776&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084352776&partnerID=8YFLogxK
U2 - 10.3389/fncel.2020.00107
DO - 10.3389/fncel.2020.00107
M3 - Review article
C2 - 32390804
AN - SCOPUS:85084352776
VL - 14
JO - Frontiers in Cellular Neuroscience
JF - Frontiers in Cellular Neuroscience
SN - 1662-5102
M1 - 107
ER -